In-vivo CAR-T is the rage and it may work, but it is not clear it has the durability or long-term efficacy of ex-vivo. In general, I bet ex vivo in multiple applications will get cheaper and will win in some big verticals.
AI Drug Discovery Is Working. That May Be the Problem
"AI is making pharma better at producing 'plausible' clinical candidates. That is real progress. But plausible clinical candidates were not the thing pharma was shortest of."
https://t.co/svTxr184rJ